Involvement of the DLK-JNK-cJun pathway in AD was further confirmed by validating the neuroprotection of VX-680 [101] (a different DLK inhibitor), GNE-495 [102] (MAP4K4 inhibitor upstream of DLK45), PF06260933 (a different MAP4K4 inhibitor), and JNK-IN-8 (JNK1/2/3 inhibitor) [93]. The gene discussed is MAPK8; the disease is Alzheimer disease.